MINNEAPOLIS--(BUSINESS WIRE)--The first device to allow physicians to access smaller, harder-to-reach lung lesions has received 510(k) clearance from the Food and Drug Administration (FDA). The inReachTM System, developed by Minneapolis-based superDimension (www.superdimension.com), provides electromagnetic navigation and guidance to distant regions of the lungs in a minimally-invasive manner, enabling doctors to diagnose lung cancer at earlier stages and potentially provide treatment sooner. The company recently raised nearly $21 million in venture capital to expand its sales, marketing and operations.
